04.

News

Find out the latest news about NextCell
2023-03-28

NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.
Read moreRead more
2023-03-21

NextCell’s CSO elected to ISCT European Regional Secretary

NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been officially elected to the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
Read moreRead more
2023-03-07

NextCell’s CSO nominated for ISCT European Regional Secretary

NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been nominated for the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
Read moreRead more
2023-01-26

NextCell publishes its Interim Report 1 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Ma
Read moreRead more
2023-01-25
ProTrans study in COVID-19 expanded to include treatment of severe pneumonia induced by influenza A, RSV and HMP virus
NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has approved the expansion of their Swedish COVID-19 study, to include patients with severe pneumonia due to influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (HMP). The treatment is aimed
Read moreRead more
2023-01-18
Positive feedback on the paediatric plan of the EMA
NextCell Pharma AB ("NextCell") has received positive comments and recommendations for the pediatric investigational plan (PIP) submitted to the Europeans Medicines Agency’s (EMA) pediatric committee (PDCO).
Read moreRead more
2022-12-21
First pediatric patients treated with ProTrans in type-1 diabetes phase II study
NextCell Pharma AB ("NextCell") supports the pediatric diabetes clinical trial conducted at Uppsala University Hospital by Principal Investigator Professor Per-Ola Carlsson with the stromal cell treatment, ProTrans. At the end of October 2022, the Data Safety and Monitoring Board recommended that ph
Read moreRead more
2022-10-27
NextCell presentation of Interim analysis data today at 15:00
NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology where stem cells can be selected for allogeneic treatment of various specific diseases. CEO Mathias Svahn will present the results on Thursday, October 27 at 15:00 CET, which will be broadca
Read moreRead more
2022-10-27
NextCell publishes its Year-End Report 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2021 – August 31, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Marke
Read moreRead more
2022-10-24
NextCell cell therapy shows long-term effect in two independent diabetes studies "ProTrans-Repeat" and "ProTrans-Obs" – live presentation
NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology where stem cells can be selected for allogeneic treatment of various specific diseases. CEO Mathias Svahn will present the results on Thursday, October 27 at 15:00 CET, which will be broad
Read moreRead more
2022-10-20
ProTrans cell therapy provides long-term effect in type-1 diabetes with a single treatment
NextCell Pharma AB ("NextCell" or the "Company") today announces that patients who 3 years ago were treated with ProTrans in the phase II study ProTrans-2 have maintained significantly higher endogenous insulin production than patients who received placebo, (63% compared to 23%). The results from th
Read moreRead more
2022-10-18
ProTrans cell therapy maintains insulin production effect 3.5 years after treatment
NextCell Pharma AB ("NextCell" or the "Company") today announces that type-1 diabetes patients receiving two treatments with a high dose of ProTrans cell therapy maintain a significantly higher endogenous insulin production than patients treated with low or medium doses.
Read moreRead more

News

16/12/2020
Interview with the CEO in Biostock
NextCell Pharma's CEO has a clear vision
Read more
10/12/2020
Article in Biostock
A right issue will enable a Phase III study
Read more
15/6/2020
Interview with the CEO in Biostock
NextCell Pharma wants to rethink the treatment paradigm for diabetes.
Read more
10/6/2020
Article about NextCell Pharma in Biostock
NextCell Pharma will pass several milestones via share issue
Read more
6/5/2020
Interview with NextCell Pharma's CEO Mathias Svahn
Our fully recruited Phase 2-study is almost finished and we see no risk for delays despite the current pandemic. The results are as expected for Q3.
Read more
6/4/2020
The stem cell treatment that could stop diabetes
Diabetes is increasing among children and young people. Today the disease is incurable, but the stem cell company NextCell Pharma believes that diabetes and several other diseases could be treated with stem cells.
Read more

Company Presentations

Ladda ner

Expert Event

Independent diabetes and cell therapy experts comment on data published.
Ladda ner

News announcement

NextCell Pharma - ProTrans shows significant effect in diabetes
Ladda ner

Aktiespararnas aktiedag, 2020-05-04

CEO Mathias Svahn presents the company (in Swedish)
Ladda ner

Elevator Pitch

A short video where CEO Mathias Svahn introduces the company

Company Analyses

6/17/2019
Analyst Group
Bull & Bear-Analysis
New capital enables completion of Phase I/II
Read more
6/13/2019
SvD Näringsliv
Nextcell Pharma: A rare investment opportunity
The stem cell company NextCell is currently issuing new shares to finance the ongoing development of their drug candidate ProTrans. (Article in Swedish)
Read more
8/10/2018
Analyst Group
Bull & Bear-Analysis
Unique stem cell company with potential within several diseases
Read more